Journal of medical biochemistry · 2026
Diagnostic and prognostic value of serum markers CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 in colon cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Song Ze, Tang Jun, Wu Min, Li Zhi, Zhang Yingqiang
Аннотация
BACKGROUND: This study aimed to assess the clinical utility of serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50, CA19-9, CA72-4, and the cytokeratin 19 fragment (CYFRA21-1) - for early detection and prognostic evaluation in colon cancer.
METHODS: A total of 50 patients diagnosed with colon cancer and 50 healthy individuals were enrolled. Serum levels of CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 were quantified and compared between groups. Correlations with tumour staging, recurrence, and metastasis were also analysed.
RESULTS: All five serum markers were significantly elevated in colon cancer patients compared to controls (P< 0.05). Marker levels were notably higher in advanced-stage cases (stages III-IV) than in early-stage disease (stages I-II) (P< 0.05). Following surgery, marker levels declined significantly (P< 0.05), except in patients with recurrence or metastasis, who showed elevated preoperative values (P< 0.05). Combined detection yielded significantly higher positive detection rates, sensitivity, and specificity than individual marker assessments (P< 0.05).
CONCLUSIONS: CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 are clinically relevant markers for the detection, staging, and prognostic prediction of colon cancer. Combined serum marker analysis substantially improves diagnostic precision and supports early screening and outcome assessment.
METHODS: A total of 50 patients diagnosed with colon cancer and 50 healthy individuals were enrolled. Serum levels of CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 were quantified and compared between groups. Correlations with tumour staging, recurrence, and metastasis were also analysed.
RESULTS: All five serum markers were significantly elevated in colon cancer patients compared to controls (P< 0.05). Marker levels were notably higher in advanced-stage cases (stages III-IV) than in early-stage disease (stages I-II) (P< 0.05). Following surgery, marker levels declined significantly (P< 0.05), except in patients with recurrence or metastasis, who showed elevated preoperative values (P< 0.05). Combined detection yielded significantly higher positive detection rates, sensitivity, and specificity than individual marker assessments (P< 0.05).
CONCLUSIONS: CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 are clinically relevant markers for the detection, staging, and prognostic prediction of colon cancer. Combined serum marker analysis substantially improves diagnostic precision and supports early screening and outcome assessment.